YBX1 and hepatocellular carcinoma: Finally, we examined YBX1 levels in the 60 sorafenib-treated HCC patients and found that patients with lower YBX1 levels were associated with better RFS (Fig. 3s and Table 2) and better OS (Fig. 3t and Supplementary Table 3).